Literature DB >> 9855152

Immediate argon laser peripheral iridoplasty as treatment for acute attack of primary angle-closure glaucoma: a preliminary study.

D S Lam1, J S Lai, C C Tham.   

Abstract

OBJECTIVE: This study aimed to examine the intraocular pressure (IOP)-lowering effects and safety of immediate argon laser peripheral iridoplasty (ALPI) as a first-line treatment for acute primary angle-closure glaucoma (PACG).
DESIGN: A prospective cohort study. PARTICIPANTS: Ten consecutive patients with their first attack of PACG, with IOP of 40 mmHg or greater, were recruited into the study. INTERVENTION: On presentation, each patient received topical pilocarpine (4%) and timolol (0.5%) and immediate ALPI as primary treatment. The IOPs at 15, 30, and 60 minutes after ALPI were documented by applanation tonometry. When the corneal edema had settled, laser peripheral iridotomy was performed as a definitive treatment. MAIN OUTCOME MEASURES: The IOP, corneal edema, and complications from ALPI were measured.
RESULTS: The mean IOP of this group of patients was reduced from 59.5+/-10.4 mmHg to 28.7+/-14.9 mmHg at 15 minutes, 21.7+/-13.1 mmHg at 30 minutes, and 16.0+/-9.4 mmHg at 60 minutes after ALPI. No complications from the laser procedure were encountered during the study period. In nine of the ten patients, the corneal edema cleared up 1 hour after ALPI. In the remaining patient, the cornea cleared up 2 hours after ALPI.
CONCLUSION: From this preliminary study, immediate ALPI, without adjunctive systemic antiglaucoma treatment, appeared to be very effective in controlling the IOP and returning corneal clarity in acute PACG. Its safety also appeared reassuring and did not have the risks associated with conventional systemic therapies.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9855152     DOI: 10.1016/s0161-6420(98)92237-0

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  7 in total

Review 1.  Laser peripheral iridoplasty for angle-closure.

Authors:  Wai Siene Ng; Ghee Soon Ang; Augusto Azuara-Blanco
Journal:  Cochrane Database Syst Rev       Date:  2012-02-15

2.  Efficacy and safety of intravenous injection of lidocaine in the treatment of acute primary angle-closure glaucoma: a pilot study.

Authors:  Xiuming Jin; Anquan Xue; Yune Zhao; Qin Qin; Xiang-Da Eric Dong; Jia Qu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-04-17       Impact factor: 3.117

3.  Primary acute angle closure: long-term clinical outcomes over a 10-year period in the Chinese population.

Authors:  Jacky W Y Lee; Billy K T Wong; Doris W F Yick; Ian Y H Wong; Can Y F Yuen; Jimmy S M Lai
Journal:  Int Ophthalmol       Date:  2013-06-04       Impact factor: 2.031

Review 4.  Acute primary angle closure-treatment strategies, evidences and economical considerations.

Authors:  Poemen P Chan; Jason C Pang; Clement C Tham
Journal:  Eye (Lond)       Date:  2018-11-22       Impact factor: 3.775

5.  Survival analysis of phacomorphic glaucoma at a tertiary hospital in North India.

Authors:  Richa Gupta; Surabhi Agrawal; Lokesh Chauhan
Journal:  Taiwan J Ophthalmol       Date:  2021-04-15

6.  A comparison of two approaches to managing acute primary angle closure in Asian eyes.

Authors:  Henrietta Ho; Paul T Chew; Chelvin Sng; Huiqi Huang; Tin Aung; Shamira A Perera
Journal:  Clin Ophthalmol       Date:  2013-06-18

7.  Argon laser peripheral iridoplasty versus systemic intraocular pressure-lowering medications as immediate management for acute phacomorphic angle closure.

Authors:  Jacky Wy Lee; Jimmy Sm Lai; Doris Wf Yick; Can Yf Yuen
Journal:  Clin Ophthalmol       Date:  2013-01-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.